ReviewThe European journal of health economics : HEPAC : health economics in prevention and care2017
Cost of diabetic eye, renal and foot complications: a methodological review.
Review in The European journal of health economics : HEPAC : health economics in prevention and care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Cost-of-Illness of Skin Cancer: A Systematic Review.PharmacoEconomics · 2024Pooled it
- Article
- From Design to Clinical Translation: Unraveling Orthotist Perspectives on 3D Printed Accommodative Insoles.Journal of prosthetics and orthotics : JPO · 2024Article
- Healthcare costs of cancer among children, adolescents, and young adults: A scoping review.Cancer medicine · 2024Article
- Unraveling shared risk factors for diabetic foot ulcer: a comprehensive Mendelian randomization analysis.BMJ open diabetes research & care · 2023Article
- Evaluation of novel plantar pressure-based 3-dimensional printed accommodative insoles - A feasibility study.Clinical biomechanics (Bristol, Avon) · 2022Article
- Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study.Journal of diabetes and metabolic disorders · 2022Article
- Direct medical cost of nephropathy in patients with type 2 diabetes.International urology and nephrology · 2022Article
- Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- War on Diabetes in Singapore: a policy analysis.Health research policy and systems · 2021Article
- Economic evaluations and cost analyses in posttraumatic stress disorder: a systematic review.European journal of psychotraumatology · 2020Review
- The Evolving Treatment of Diabetic Retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Amputation-free survival in 17,353 people at high risk for foot ulceration in diabetes: a national observational study.Diabetologia · 2018Observational
- Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic retinopathy (DR), diabetic kidney disease (DKD) and diabetic foot ulcer (DFU) represent a public health and economic concern that may be assessed with cost-of-illness (COI) studies.
objectives(1) To review COI studies published between 2000 and 2015, about DR, DKD and DFU; (2) to analyse methods used.
methodsDisease definition, epidemiological approach, perspective, type of costs, activity data sources, cost valuation, sensitivity analysis, cost discounting and presentation of costs may be described in COI studies. Each reviewed study was assessed with a methodological grid including these nine items.
resultsThe five following items have been detailed in the reviewed studies: epidemiological approach (59 % of studies described it), perspective (75 %), type of costs (98 %), activity data sources (91 %) and cost valuation (59 %). The disease definition and the presentation of results were detailed in fewer studies (respectively 50 and 46 %). In contrast, sensitivity analysis was only performed in 14 % of studies and cost discounting in 7 %. Considering the studies showing an average cost per patient and per year with a societal perspective, DR cost estimates were US $2297 (range 5-67,486), DKD cost ranged from US $1095 to US $16,384, and DFU cost was US $10,604 (range 1444-85,718). DISCUSSION: This review reinforces the need to adequately describe the method to facilitate literature comparisons and projections. It also recalls that COI studies represent complementary tools to cost-effectiveness studies to help decision makers in the allocation of economic resources for the management of DR, DKD and DFU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.